Sunshine Biopharmaの空売り状況は、投資家がSunshine Biopharmaの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sunshine Biopharma (NASDAQ:SBFM) 株価情報, 空売り情報

Sunshine Biopharma

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Sunshine Biopharma Inc

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares moved upwards by 179.6% to $0.63 during Thursday's pre-market session. The company's market cap stands at $4.5 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock increased by 122.46% to $3.07. The company's market cap stands at $4.4 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock increased by 62.76% to $5.29. The company's market cap stands at $3.2 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock moved upwards by 44.95% to $2.13. The company's market cap stands at $41.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 21.08% to $0.36. The company's market cap stands at $3.0 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 13.64% to $0.15. The market value of their outstanding shares is at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) stock fell 29.2% to $18.49 during Thursday's pre-market session. The market value of their outstanding shares is at $748.7 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares fell 24.18% to $0.67. The market value of their outstanding shares is at $10.5 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) stock fell 23.01% to $4.1. The market value of their outstanding shares is at $244.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock fell 22.95% to $0.23. The company's market cap stands at $4.6 million. </li>
<li>ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) stock fell 20.11% to $4.61. The market value of their outstanding shares is at $176.0 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 19.56% to $1.81. The market value of their outstanding shares is at $4.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALDX

APVO

BIAF

GNPX

ITOS

OSRH

PTIX

QNRX

RXST

SBFM

TIVC

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

FORT LAUDERDALE, FL / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction has been priced at the market under Nasdaq rules.
The offering consisted of the sale of 1,188,404 shares of Common Stock (or Pre-Funded Warrants). The offering price per Common Share is $2.07 (or $2.069 for each Pre-Funded Warrant, which is equal to the offering price per share of Common Stock to be sold in the offering minus an exercise price of $0.001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full.

News

Offerings

Sunshine Biopharma Announces $2.46M Registered Direct Offering At $2.07 A Share

<h3>Gainers</h3>
<ul>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock rose 48.2% to $0.32 during Wednesday's regular session. The company's market cap stands at $29.0 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares moved upwards by 43.52% to $3.1. The market value of their outstanding shares is at $4.9 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares rose 43.37% to $0.33. The company's market cap stands at $2.8 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares rose 33.97% to $0.32. The company's market cap stands at $58.3 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock moved upwards by 30.52% to $2.71. The market value of their outstanding shares is at $7.3 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares increased by 29.62% to $9.38. The market value of their outstanding shares is at $510.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock fell 67.3% to $0.52 during Wednesday's regular session. The company's market cap stands at $1.7 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock declined by 35.72% to $0.17. The market value of their outstanding shares is at $2.0 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 28.42% to $0.59. The market value of their outstanding shares is at $6.7 million. </li>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) shares decreased by 24.05% to $15.29. The company's market cap stands at $1.4 billion. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock fell 23.89% to $8.57. The market value of their outstanding shares is at $193.3 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock declined by 22.31% to $0.32. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

ALMS

EWTX

NTHI

PCSA

RSLS

SCLX

SYRA

TCRT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) traded higher on Wednesday, with a session volume of 19.07 million compared to an average volume of 88.16K, according to data <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">from Benzinga Pro</a>.
The company on Wednesday announced that it has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) product as a therapeutic agent for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44604670/sunshine-biopharma-announces-positive-results-of-mrna-therapy-for-cancer" rel="noreferrer noopener">human hepatocellular carcinoma</a>.
Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancer in adults.
The company optimized the expression level of its full-length mRNA (K1.1c) and as a smaller, truncated version (K1.1d) in <a href="https://www.benzinga.com/pressreleases/25/04/ac44604670/sunshine-biopharma-announces-positive-results-of-mrna-therapy-for-cancer" target="_blank" rel="noreferrer noopener">HCC tumors in mice</a>.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592055/knight-swift-faces-pressure-with-lack-of-freight-flows-amid-tariffs-analyst-downgrades-stock" target="_blank" rel="noreferrer noopener">Knight-Swift Faces Pressure With Lack Of Freight Flows Amid Tariffs, Analyst Downgrades Stock</a>
Following encapsulation in two specifically designed Lipid Nanoparticles, the resulting K1.1c-mRNA-LNP and K1.1d-mRNA-LNP were efficiently delivered to orthotopic engrafted HCC tumors in mice in a dose-dependent manner by systemic administration.
Under repeated dosing, the full-length K1.1c reduced the growth of three different types of human HCC tumors in mice with good tolerability.
A proof-of-concept study of the truncated version K1.1d was conducted to assess its anti-tumor activity in HCC mice models.
A preliminary study suggested that the truncated form of K1.1c could be highly expressed in engrafted tumors and had significant, dose-dependent anti-tumor activity in mouse HCC models.
The company is conducting additional animal studies to delineate the optimum dosing of the truncated version (K1.1d) in a different HCC model to compare its dose-response and therapeutic window with the full-length version (K1.1c).
The smaller-sized mRNA of the truncated version offers the advantage of better efficacy at lower doses.
On Tuesday, Sunshine Biopharma reported 2024 revenue of $34.9 million, up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44596426/sunshine-biopharma-reports-revenue-of-34-9m-in-fiscal-2024-up-45-from-last-year" rel="noreferrer noopener">45% year over yea</a>r.
Price Action: SBFM stock is up 69.2% at $3.52 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/04/44592941/tariff-tensions-could-hurt-us-gdp-as-canadian-tourism-cools-goldman-sachs" target="_blank" rel="noreferrer noopener">Tariff Tensions Could Hurt US GDP As Canadian Tourism Cools: Goldman Sachs</a></li>
</ul>

Biotech

Earnings

Health Care

Trading Ideas

General

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug

WIIM

Sunshine Biopharma shares are trading higher after the company reported a year-over-year increase in FY24 revenue results.

<h3>Gainers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 59.1% to $3.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 55.48% to $0.33. The company's market cap stands at $6.7 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 26.21% to $0.52. The company's market cap stands at $2.7 million. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) shares rose 17.71% to $10.9. The market value of their outstanding shares is at $143.2 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares increased by 17.61% to $0.4. The company's market cap stands at $20.9 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares increased by 12.8% to $1.65. The market value of their outstanding shares is at $13.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock fell 64.7% to $0.56 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock declined by 46.47% to $0.14. The market value of their outstanding shares is at $1.7 million. </li>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock declined by 30.51% to $13.99. The company's market cap stands at $1.3 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.44% to $0.64. The company's market cap stands at $7.4 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 19.17% to $0.07. The market value of their outstanding shares is at $1.7 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) stock decreased by 16.89% to $5.71. The market value of their outstanding shares is at $227.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRIS

GLSI

LUNG

PTPI

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.
As the &#8220;Liberation Day&#8221; has arrived, traders will look for cues from President Donald Trump&#8217;s &#8220;reciprocal tariffs&#8221; scheduled to be announced later today.
The administration is reportedly considering a widespread 20% tariff that would affect a large portion of the $3 trillion in yearly imports, according to <a href="https://www.washingtonpost.com/business/2025/04/01/trump-tariffs-draft-recession-projection/">a</a> Washington Post report.
The 10-year Treasury bond yielded 4.17% and the two-year bond was at 3.88%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in an 85.5% likelihood of the Federal Reserve maintaining current interest rates through its May meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.17%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.22%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.29%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.30%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Tuesday. The SPY was down 0.25% to $559.58, while the QQQ declined 0.34% to $471.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Driven by gains in consumer discretionary, communication services, and information technology, the S&amp;P 500 closed slightly higher on Tuesday, though overall U.S. stocks settled mixed.
Conversely, the health care and financial sectors experienced declines. This sector divergence occurred as investors anticipated the Trump administration&#8217;s upcoming tariff announcements.
Meanwhile, broader market indices reflected significant losses for March and the first quarter of the year: the S&amp;P 500 saw its largest monthly drop since December 2022, falling 5.8%, while the Nasdaq and Dow tumbled 8.2% and 4.2% respectively. Quarterly, the Nasdaq declined 10.4%, the Dow 1.3%, and the S&amp;P 500 also recorded a loss.
Economic data revealed a decline in the ISM manufacturing PMI, an increase in construction spending, and a decrease in job openings.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.67%</td>
<td>17,449.89</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.38%</td>
<td>5,633.07</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.028%</td>
<td>41,989.96</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.016%</td>
<td>2,012.24</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As investors await further direction on the economy&#8217;s outlook after Trump&#8217;s tariffs, Jurrien Timmer, the director of global macro at Fidelity Investments, in his <a href="https://www.linkedin.com/pulse/study-contrasts-week-33125-jurrien-timmer-gjkwe/">recent note</a> said that &#8220;More uncertainty means higher risk premia.&#8221;
Th refers to the additional return investors expect to receive for taking on a riskier investment compared to a risk-free investment. It&#8217;s essentially the reward for bearing greater uncertainty.
He observes a significant shift in market sentiment, moving from confidence to doubt. He notes, &#8220;Markets continue to price in a possible left tail,&#8221; with the S&amp;P 500 hovering at the -10% correction threshold.
Timmer distinguishes between sharp, swift drawdowns, like the 1998 LTCM crisis, and potential recession-driven corrections. &#8220;Market cycles that are priced for recessions that don't happen are the ones we want to rebalance into.&#8221; However, he cautions that if fiscal austerity and trade tensions trigger a recession, &#8220;we are likely not done correcting.&#8221; The core-PCE inflation rate near 3% further complicates matters, potentially limiting the Fed&#8217;s support.
While acknowledging the difficulty of predicting market movements in real time, he emphasizes the importance of analyzing &#8220;the tape, sentiment, valuation, earnings estimates, and credit.&#8221; While the market appears &#8220;moderately oversold&#8221; and sentiment is cautious, it doesn&#8217;t indicate recessionary pricing, warranting &#8220;further patience.&#8221;
Regarding diversification, Timmer points to the performance of international equities, Treasuries, and gold. He also poses the crucial question: &#8220;whether the rotation out of the Mag 7 is a bump along the road to continued AI and mega cap dominance, or the BIG one.&#8221; He stresses that if a new secular regime is emerging, &#8220;the game going forward will be all about the alpha instead of the beta,&#8221; necessitating a wider asset allocation and lower equity return expectations.
Timmer also notes the historical occurrence of 10% drawdowns, stating &#8220;The odds of being in a 10% drawdown have been around 40% for the S&amp;P 500,&#8221; and that there is no clear historical pattern of what happens after a 10% decline. He also notes a similarity between the current market and the 1998 LTCM crisis, both catalyzed by an unwinding of crowded trades.
According to Eugenia Mykuliak, the founder and executive director at B2PRIME Group, tariffs can cause a disruption in global supply chains, which will lead businesses to reassess their supply routes.
A recalibration of the supply chain will lead to &#8220;Capital outflows from emerging markets and increased market volatility,&#8221; said Mykuliak.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>March&#8217;s ADP employment data will be out by 8:15 a.m. ET.</li>
</ul>
<ul>
<li>February&#8217;s factory orders data will be released at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Adriana Kugler will speak at 4:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>UniFirst Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) was up 0.36% in premarket on Wednesday ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of $1.34 per share on revenue of $602.80 million.</li>
</ul>
<ul>
<li>BlackBerry Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) advanced 3.22% as Wall Street expects it to report a quarterly earnings of 1 cent per share on revenue of $132.83 million before the opening bell.</li>
</ul>
<ul>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose 2.07% ahead of its earnings after the closing bell. Analysts expect a quarterly earnings of $1.92 per share on revenue of $829.56 million.</li>
</ul>
<ul>
<li>Sportsman&#8217;s Warehouse Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) jumped 31.61% after posting stronger-than-expected earnings and sales results for its fourth quarter on Tuesday.</li>
</ul>
<ul>
<li>nCino Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) plunged 31.33%, reporting weaker-than-expected earnings for its fourth quarter, while sales topped estimates. The company also said it sees first-quarter total revenue of $138.75 million to $140.75 million and adjusted earnings of 15 cents to 16 cents per share.</li>
</ul>
<ul>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) was 0.45% lower after completing its $4.9 billion acquisition of data-center equipment designer ZT Systems.</li>
</ul>
<ul>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) slumped 59.24% after it announced a voluntary delisting from the Nasdaq Capital Market.</li>
</ul>
<ul>
<li>Seritage Growth Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRG#NYSE">SRG</a>) declined 29.29% after it generated $61.8 million in asset sales, but reported a $158.4 million net loss for the year.</li>
</ul>
<ul>
<li>Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) surged 54.77% after its 2024 revenue surged to $34.9 million from $24.1 million in the year-ago period.</li>
</ul>
<ul>
<li>Antelope Enterprise Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) plummeted 30.05% after announcing a 1-for-40 reverse stock split.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.13% to hover around $71.11 per barrel.
Gold Spot US Dollar advanced 0.30% to hover around $3,133.45 per ounce. Its fresh record high stood at $3,149.03 per ounce. The U.S. Dollar Index spot was lower by 0.11% at the 104.144 level.
Asian markets closed on a mixed note on Wednesday. Japan's Nikkei 225 and Australia's ASX 200 index advanced. Whereas China&#8217;s CSI 300, Hong Kong's Hang Seng, and South Korea's Kospi index fell. European markets were also mixed in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44601482/gold-holds-above-3100-mark-price-surge-reflects-growing-economic-uncertainty-here-are-some">Gold Holds Above $3,100 Mark Amid Growing Economic Uncertainty: Here Are Some ETFs To Capitalize On The Golden Rush</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Market Summary

Futures

Commodities

Forex

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

AEHL

NCNO

SPWH

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

Shares of Sportsman&#8217;s Warehouse Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) rose sharply in today's pre-market trading after the company posted stronger-than-expected earnings and sales results for its <a href="https://in.benzinga.com/general/sports/25/04/44595938/sportsmans-warehouse-stock-soars-on-q4-earnings-revenue-beat-eps-beat-taking-share-in-core-categories-and-more">fourth quarter on Tuesday</a>.
Sportsman's Warehouse reported fourth-quarter revenue of $340.4 million, beating analyst estimates of $329.61 million, according to Benzinga Pro. Total revenue was down 8.1% on a year-over-year basis. The outdoor specialty retailer reported fourth-quarter adjusted earnings of four cents per share, beating estimates for a loss of six cents per share. Adjusted EBITDA was $14.6 million in the quarter.
Sportsman's Warehouse expects full-year 2025 net sales to be in the range of down 1% to up 3.5%. The company anticipates full-year adjusted EBITDA of $33 million to $45 million.
Sportsman&#8217;s Warehouse shares jumped 38.8% to $1.34 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Digital Ally, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) gained 159.6% to $0.0675 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) rose 93.1% to $3.07 in pre-market trading after jumping 341% on Tuesday.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) rose 56.9% to $3.28 in pre-market trading. Sunshine Biopharma reported that 2024 revenue surged to $34.9 million from $24.1 million in the year-ago period.</li>
<li>Innovation Beverage Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBG#NASDAQ">IBG</a>) gained 44.1% to $0.7134 in pre-market trading.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) surged 28.2% to $0.0555 in pre-market trading after dipping around 8% on Tuesday.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) rose 26.6% to $1.38 in pre-market trading. BioAffinity Technologies shares jumped 319% on Tuesday following a year-over-year increase in FY24 financial results.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) gained 23.1% to $0.0336 in pre-market after falling 9% on Tuesday.</li>
<li>Mister Car Wash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NASDAQ">MCW</a>) gained 12.3% to $8.89 in pre-market trading.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) gained 11.7% to $7.78 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Jayud Global Logistics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) shares fell 78.3% to $0.3490 in pre-market trading.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) fell 59.8% to $0.1085 in pre-market trading after the company announced voluntary delisting from the Nasdaq Capital Market.</li>
<li>Quad/Graphics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) declined 45.5% to $3.01 in pre-market trading.</li>
<li>nCino, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) fell 31.5% to $19.30 in pre-market trading after the company reported weaker-than-expected earnings for its fourth quarter, while sales topped estimates. The company also said it sees first-quarter total revenues of $138.75 million to $140.75 million and adjusted earnings of 15 cents to 16 cents per share.</li>
<li>Seritage Growth Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRG#NYSE">SRG</a>) fell 29.3% to $2.10 in today's pre-market trading after dipping 8% on Tuesday. Seritage Growth Properties, on Monday, posted a fourth-quarter loss of 22 cents per share, versus a year-ago profit of 8 cents per share.</li>
<li>Waton Financial Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) shares tumbled 28% to $14.30 in pre-market trading after jumping 396% on Tuesday.</li>
<li>Silvercrest Asset Management Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) fell 26.7% to $12.10 in pre-market trading.</li>
<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) dipped 26.4% to $0.0705 in pre-market trading. Antelope Enterprise announced a 1-for-40 reverse stock split.</li>
<li>Rapport Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) shares dipped 24.7% to $7.20 in pre-market trading following a 5% decline on Tuesday.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) shares fell 21.2% to $183.73 in pre-market trading. Newsmax shares surged 179% on Tuesday on continued IPO launch strength.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44600914/unifirst-blackberry-and-3-stocks-to-watch-heading-into-wednesday">UniFirst, BlackBerry And 3 Stocks To Watch Heading Into Wednesday</a> </li>
</ul>
Photo via Danille Nicole Wilson/Shutterstock

AGMH

DGLY

GRFS

NMAX

QUAD

RAPP

SAMG

STSS

Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket

Sunshine Biopharma 2024 Revenue $34.9M Up From $24.1M YoY

Sunshine Biopharma Acquires Marketing Rights For Two Generic Antibiotics In Canada

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.
The newly launched drug is Prucalopride, a generic version of Resotran&#xAE;. In the United States, Prucalopride is sold under the brand name, Motegrity&#xAE;. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.
Nora Pharma's Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg.

Sunshine Biopharma's Nora Pharma Acquires Rights To Two Gastrointestinal Drugs; Already Launched Prucalopride For Chronic Constipation, Second Drug Launch Planned In The Next 9 Months; No Financial Terms Disclosed

Sunshine Biopharma Files For Offering Of Mixed Shelf Of Up To $100M

Sunshine Biopharma Announces Development Of An Orally Active Protease Inhibitor With Dose-Dependent Antiviral Activity In Mice With SARS-CoV-2)

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has completed mouse model studies providing proof-of-concept for the Company's K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma.
Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several systematic treatment options were available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%.
When transfected into cultured human HCC cell lines and patient-derived HCC cells, K1.1 mRNA exhibited dose-dependent anti-proliferative activity in vitro. Following encapsulation in specifically engineered lipids, the resulting K1.1 mRNA-Lipid Nanoparticles (K1.1/LNP) were efficiently delivered to livers of mice in a dose-dependent manner in vivo. K1.1/LNP, under repeated systemic dosing, was found to reduce growth of two different types of human HCC tumors orthotopically grafted into the livers of immunodeficient mice. The pharmacodynamics of K1.1/LNP in intrahepatic tumors was well correlated with antitumor efficacy in mice.
We are excited about these findings which show the feasibility of K1.1 mRNA technology to not only enter malignant liver cells in a dose dependent fashion, but also in a manner that inhibits growth of these same cells" said Dr. Steve Slilaty, CEO of Sunshine Biopharma and inventor of the Company's K1.1 mRNA technology. "We are currently conducting additional animal studies to delineate the therapeutic window and optimize dosing of our K1.1/LNP for use as a single agent in future treatment of HCC patients," he added.

Sunshine Biopharma Announces Breakthrough Research Results On The Company's K1.1 mRNA Product As A Novel Therapeutic Agent For Human Hepatocellular Carcinoma; When Transfected Into Cultured Human HCC Cell Lines And Patient-Derived HCC Cells, K1.1 MRNa Exhibited Dose-Dependent Anti-Proliferative Activity In Vitro

Sunshine Biopharma shares are trading higher after its Nora Pharma subsidiary launched Ursodiol, a generic version of URSO DS.

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

Sunshine Biopharma Q3 2024 GAAP EPS $(0.94), Sales $8.435M

Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.
The first product is Varenicline, a generic version of Champix&#xAE;. Varenicline is used as a smoking cessation product and is available in formats of 0.5 mg and 1 mg tablets, as well as a convenient starter kit.
The second is Betahistine, a generic version of Serc&#xAE;, to treat patients with vertigo. Betahistine is available in formats of 8 mg, 16 mg and 24 mg scored tablets.

Sunshine Biopharma Launches Two New Generic Prescription Drugs; Varenicline, A Generic Version Of Champix; Betahistine, A Generic Version Of Serc

Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%
Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy
XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties
Research was conducted in collaboration with the University of Arizona
FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection.

Sunshine Biopharma Announces Publication Of Significant Coronavirus Research Results In The Journal Of Medicinal Chemistry

Press Releases

Sunshine Biopharma Launches a New Generic Prescription Drug

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

Comments

Sunshine Biopharma

空売り

Sunshine Biopharma (NASDAQ:SBFM) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル